Dual GIP and GLP-1 receptor agonist
PRODUCT PROFILE
Tirzepatide
£79.00
Tirzepatide is dual gip and glp-1 receptor agonist. Researchers examine it in relation to glucose-dependent insulin signalling, appetite regulation and long-term weight management.
Why it is distinct
Dual incretin agonism distinguishes it from single-target semaglutide and triple-target retatrutide.
- Evidence stageEstablished
- AvailabilityUnavailable
- Batch recordPublished after verification
- DispatchConfirmed at checkout
Out of stock
Ask about availabilityPRODUCT INFORMATION
Clear first. Detailed when needed.
What this material is+
Tirzepatide is dual gip and glp-1 receptor agonist. Researchers examine it in relation to glucose-dependent insulin signalling, appetite regulation and long-term weight management.
Research focus+
Researchers study how it can help people feel fuller, eat less and manage glucose more effectively. It is an authorised medicine in specific forms and settings, but this research listing is not a treatment recommendation.
How the mechanism differs+
Combines GIP-receptor and GLP-1-receptor agonism without the glucagon-receptor component found in retatrutide.
Evidence and limitations+
Authorised prescription medicine for defined indications, supported by large phase 3 programmes and post-authorisation safety monitoring.
Testing and batch documentation+
No live certificate is shown for this staging item. ADINA will only publish a batch document after the product identifier, test method and result have been checked.
RESEARCH PROFILE
Understand the distinction.
Researchers study how it can help people feel fuller, eat less and manage glucose more effectively. It is an authorised medicine in specific forms and settings, but this research listing is not a treatment recommendation.
Combines GIP-receptor and GLP-1-receptor agonism without the glucagon-receptor component found in retatrutide.
Dual incretin agonism distinguishes it from single-target semaglutide and triple-target retatrutide.
Authorised prescription medicine for defined indications, supported by large phase 3 programmes and post-authorisation safety monitoring.
Educational research context only. This information is not dosage, administration or personal-use guidance.
CONTINUE EXPLORING
Related research perspectives.
Selected for useful comparison across neighbouring or contrasting research areas—not as combined-use guidance.
-
Phase 2 clinical research
MOTS-c
£35.64Batch file pendingMOTS-c begins inside mitochondria and is studied for cell-wide energy adaptation, rather than directly targeting appetite receptors.
Available · 30 in stockAdd to basket -
Clinical research
SS-31 (Elamipretide)
£29.9910 mgBatch file pendingDirectly targets mitochondrial membrane cardiolipin, unlike MOTS-c’s signalling-peptide role.
UnavailableAsk about availability -
Preclinical
BPC-157
£32.99Batch file pendingBPC-157 is mainly discussed around stomach and local tissue-repair models. TB-500 is instead studied for actin, cell movement…
Available · 30 in stockAdd to basket -
Phase 2 clinical research
GHK-Cu
£24.99Batch file pendingGHK-Cu is a copper complex. Pal-GHK has a fatty tail for topical formulas, while non-copper peptides use different…
Available · 50 in stockAdd to basket